Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Pancreatic Neoplasms 63Breast Neoplasms 63Carcinoma, Non-Small-Cell Lung 39Triple Negative Breast Neoplasms 29Ovarian Neoplasms 25Fallopian Tube Neoplasms 22Squamous Cell Carcinoma of Head and Neck 17Lung Neoplasms 16Stomach Neoplasms 11Neoplasm Metastasis 11Neoplasms 9Inflammatory Breast Neoplasms 9Breast Neoplasms, Male 9Melanoma 7Esophageal Neoplasms 7Cholangiocarcinoma 7Uterine Cervical Neoplasms 6Esophageal Squamous Cell Carcinoma 6Endometrial Neoplasms 6Carcinoma, Ovarian Epithelial 6Pancreatic Adenocarcinoma 5Gallbladder Neoplasms 5Adenocarcinoma Of Esophagus 5Adenocarcinoma 5Urinary Bladder Neoplasms 4Recurrence 4Carcinoma, Transitional Cell 4Biliary Tract Neoplasms 4Prostatic Neoplasms 3Peritoneal Neoplasms 3

Interventions

Dexamethasone 420Lenalidomide 265Cyclophosphamide 246Bortezomib 242Melphalan 192Calcium Dobesilate 166fludarabine phosphate 112daratumumab 103Peripheral Blood Stem Cell Transplantation 99carfilzomib 92Thalidomide 90Filgrastim 88Mycophenolic Acid 82fludarabine 81pomalidomide 80Whole-Body Irradiation 80Busulfan 74Tacrolimus 71Granulocyte Colony-Stimulating Factor 66Cyclosporine 58dexamethasone acetate 56ixazomib 55Antilymphocyte Serum 50dexamethasone 21-phosphate 49auricularum 44isatuximab 40Etoposide 39Radiotherapy 36Stem Cell Transplantation 34Methotrexate 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Multiple Myeloma × Taxes × Clear all
NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT01646762 2017-10-16

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple Myeloma

Mayo Clinic

Phase 2 Terminated
13 enrolled 11 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡